| Name | Licogliflozin |
|---|---|
| Synonyms |
(2S,3R,4R,5S,6R)-2-[3-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YLMETHYL)-4-ETHYL-PHENYL]-6-HYDROXYMETHYL-TETR
LIK066 D-Glucitol, 1,5-anhydro-1-C-[3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-ethylphenyl]-, (1S) SGLT,LIK 066,LIK-066,Licogliflozin,inhibit,Sodium-dendent glucose cotransporters,Inhibitor Licogliflozin (LIK066) (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol licogliflozin bis(prolinate) (2S,3R,4R,5S,6R)-2-(3-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Description | Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. |
|---|---|
| Related Catalog | |
| Target |
SGLT1, SGLT2[1] |
| In Vitro | Licogliflozin (LIK066) is a non-anti-fibrotic treatment agent for non-alcoholic steatohepatitis (NASH). |
| References |
| Molecular Formula | C23H28O7 |
|---|---|
| Molecular Weight | 416.46 |
| Storage condition | 2-8℃ |